Skip to main content
Fig. 4 | Journal of Nanobiotechnology

Fig. 4

From: Nectin-4-targeted immunoSPECT/CT imaging and photothermal therapy of triple-negative breast cancer

Fig. 4

In vitro biological safety, targeting and PTT effects of mAbNectin-4-ICG. a Cytotoxicity of mAbNectin-4-ICG and free ICG containing different ICG concentrations on MDA-MB-468 cells (n = 5). b, c In vitro cell targeting study of mAbNectin-4-ICG and corresponding fluorescence quantitative analysis. d–f The viability of MDA-MB-468 cells after different treatments. ICG concentration-dependent PTT (d) was performed with 1.0 W/cm2 power for 10 min following cells treated with graded ICG concentrations; power density-dependent PTT (e) was performed at graded laser power densities for 10 min following cells treated with mAbNectin-4-ICG/free ICG (20 μg/mL ICG); irradiated time-dependent study (f) was performed following cells treat with mAbNectin-4-ICG/free ICG (20 μg/mL ICG), and then the PTT was conducted at 1.0 W/cm2 power density for different times ranging 0–10 min; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 compared to control. g Celluar FL images of Calcein AM/PI staining following different treatment, the green signal refers to viable cells whereas the red signal refers to dead cells, scale bar = 200 µm

Back to article page